Portuguese Consensus for the Evaluation of the Multiple Sclerosis Treatment Response: A Delphi Panel
DOI:
https://doi.org/10.46531/sinapse/GU/84/2025Keywords:
Immunologic Factors/ therapeutic use, Multiple Sclerosis/drug therapy, Multiple Sclerosis/therapyAbstract
Introduction: Multiple sclerosis management has progressed significantly due to the development of novel treatments. Thus, assessing the patients’ treatment response is essential to optimize therapeutic decisions. This study aimed to establish a national consensus on the assessment and monitoring of the response to multiple sclerosis treatment with disease-modifying therapies.Methods: The Delphi methodology was employed, and two rounds of votes were performed. The statements that did not reach consensus (<80%) in the first round were submitted to a new assessment by the panel.
Results: Thirty-eight Neurologists participated in the first round and 33 participated in the second round (86.8% response rate). In total, 38 statements (71.7%) reached consensus. In a general manner, consensus was reached for the statements related to assessment and monitorization of response to treatment. Statements for which no consensus was reached were related to less established response evaluation criteria, such as assessment by optical coherence tomography. Additionally, a lack of consensus was observed for the statements where the obtained evaluation makes it difficult to define suboptimal response to treatment and for shorter or longer monitoring times.
Conclusion: This work highlights the importance of assessing the response to disease-modifying treatments in patients with multiple sclerosis and provides a set of criteria for this evaluation, established by a comprehensive panel of Portuguese experts. A more comprehensive analysis, which includes different parameters, was consensually agreed to be the best assessment strategy.
Downloads
References
Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4:43. doi: 10.1038/s41572-018-0041-4
Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26:1816-21. doi: 10.1177/1352458520970841
Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, et al. Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. Neurology. 2019;92:180-92. doi: 10.1212/WNL.0000000000006810
Brieva L, Estruch BC, Merino JA, Meca-Lallana V, Río J, Rodríguez-Antigüedad A, et al. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology. Mult Scler Relat Disord. 2022;63:10380. doi: 10.1016/j.msard.2022.103805
Amato MP, Fonderico M, Portaccio E, Pastò L, Razzolini L, Prestipino E, et al. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain. 2020;143:3013-24. doi: 10.1093/brain/awaa251
Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, et al. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. JAMA Neurol. 2010;76:536-41. doi: 10.1001/jamaneurol.2018.4905
Mirabella M, Annovazzi P, Brownlee W, Cohen JA, Kleinschnitz C, Wolf C. Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate? Front Neurol. 2022;13:844873. doi: 10.3389/fneur.2022.844873
Kalincik T, Diouf I, Sharmin S, Malpas C, Spelman T, Horakova D, et al. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology. 2021;96:e783-97. doi: 10.1212/WNL.0000000000011242
Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, et al. Optimizing treatment success in multiple sclerosis. J Neurol. 2016;263:1053-65. doi: 10.1007/s00415-015-7986-y
Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, et al. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord. 2019;12:1756286419836571. doi: 10.1177/1756286419836571
Rodrigues R, Rocha R, Bonifácio G, Ferro D, Sabença F, Gonçalves AI, et al. Therapeutic inertia in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021;55:103176. doi: 10.1016/j.msard.2021.103176
Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995;311:376-80. doi: 10.1136/bmj.311.7001.376
Rio J, Peña J, Ruiz LB, Oreja-Guevara C, Costa-Frossard L, Rodriguez-Antigüedad A, et al. Assessment and Follow-up of the Response to Disease Modifying Treatments in Multiple Sclerosis: Spanish Expert Consensus (1786). Neurology. 2020;94:1786
Calabresi PA, Kappos L, Giovannoni G, Plavina T, Koulinska I, Edwards MR, et al. Measuring treatment response to advance precision medicine for multiple sclerosis. Ann Clin Transl Neurol. 2021;8:2166-73. doi: 10.1002/acn3.51471
Lu G, Beadnall HN, Barton J, Hardy TA, Wang C, Barnett MH. The evolution of “No Evidence of Disease Activity” in multiple sclerosis. Mult Scler Relat Disord. 2018;20:231-8. doi: 10.1016/j.msard.2017.12.016
Sá MJ, de Sá J, Sousa L. Relapsing-remitting multiple sclerosis: patterns of response to disease-modifying therapies and associated factors: a national survey. Neurol Ther. 2014;3:89-99. doi: 10.1007/s40120-014-0019-4
Damasceno A, Damasceno BP, Cendes F. No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy. Mult Scler. 2016;22:64-72. doi: 10.1177/1352458515604383
Harel A, Sperling D, Petracca M, Ntranos A, Katz-Sand I, Krieger S, et al. Brain microstructural injury occurs in patients with RRMS despite ‘no evidence of disease activity’. J Neurol Neurosurg Psychiatry. 2018;89:977-82. doi: 10.1136/jnnp-2017-317606
Bevan CJ, Cree BA. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol. 2014;71:269-70. doi: 10.1001/jamaneurol.2013.5486
Zivadinov R, Havrdová E, Bergsland N, Tyblova M, Hagemeier J, Seidl Z, et al. Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology. 2013;268:831-41. doi: 10.1148/radiol.13122424
Slezáková D, Kadlic P, Jezberová M, Boleková V, Valkovic P, Minar M. Brain volume loss in multiple sclerosis is independent of disease activity and might be prevented by early disease-modifying therapy. Neurol Neurochir Pol. 2023;57:282-8. doi: 10.5603/PJNNS.a2023.0031
Chylinska M, Komendzinski J, Wyszomirski A, Karaszewski B. Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis. Mult Scler Int. 2023;2023:4130557. doi: 10.1155/2023/4130557
Andravizou A, Dardiotis E, Artemiadis A, Sokratous M, Siokas V, Tsouris Z, et al. Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options. Auto Immun Highlights. 2019;10:7. doi: 10.1186/s13317-019-0117-5
Zivadinov R, Jakimovski D, Gandhi S, Ahmed R, Dwyer MG, Horakova D, et al. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Rev Neurother. 2016;16:777-93. doi: 10.1080/14737175.2016.1181543
Rocca MA, Battaglini M, Benedict RH, De Stefano N, Geurts JJ, Henry RG, et al. Brain MRI atrophy quantification in MS: From methods to clinical application. Neurology. 2017;88:403-13. doi: 10.1212/WNL.0000000000003542
Wang C, Ruiz A, Mao-Draayer Y. Assessment and Treatment Strategies for a Multiple Sclerosis Relapse. J Immunol Clin Res. 2018;5:1032
Freedman MS, Devonshire V, Duquette P, Giacomini PS, Giuliani F, Levin MC, et al. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Can J Neurol Sci. 2020;47:437-55. doi: 10.1017/cjn.2020.66
Frederiksen J, Gasperini C, Hacohen Y, Kappos L, Li DK, Mankad K, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20:653-70. doi: 10.1016/S1474-4422(21)00095-8
Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BC, Gronseth GS, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:777-88. doi: 10.1212/WNL.0000000000005347
Direção Geral da Saúde. Terapêutica Modificadora da Esclerose Múltipla na Idade Pediátrica e no Adulto: Norma nº 005/2012 atualizada a 31/07/2015 [acedido Jan 2024] Disponível em: https://normas.dgs.min-saude.pt/2012/12/04/terapeutica-modificadora-da-esclerose-multipla-na-idade-pediatrica-e-no-adulto/
University of California, San Francisco MS-EPIC Team; Cree BC, Hollenbach JA, Bove R, Kirkish G, Sacco S, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019;85:653-66. doi: 10.1002/ana.25463
Tomassini V, Sinclair A, Sawlani V, Overell J, Pearson OR, Hall J, et al. Diagnosis and management of multiple sclerosis: MRI in clinical practice. J Neurol. 2020;267:2917-25. doi: 10.1007/s00415-020-09930-0
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Sónia Batista, Carlos Capela, Filipe Correia, João Ferreira, Joana Guimarães, Ernestina Santos, Maria José Sá (Autor)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
